> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-241/
- Published: 2019-10-06T12:00:00.000Z
- Updated: 2026-09-15T01:54:31.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5145184

[**Panel to Review Jardiance sNDA**](https://www.fdaweb.com/panel-to-review-jardiance-snda/)  
*Federal Register* notice: FDA announces an 11/13 Endocrinologic and Metabolic Drugs Advisory Committee meeting to review a Boehringer Ingelheim supplemental NDA for Jardiance. 10/04/2019

[**Clinical Data Standards Pilot: Correction**](https://www.fdaweb.com/clinical-data-standards-pilot-correction/)  
*Federal Register* notice: FDA corrects a notice that appeared in 8/20 Federal Register announcing a “Fit for Use Pilot Program Invitation for the Clinical Data Interchange Standards Consortium for Standard for Exchange of Nonclinical Data Implementation Guide.” 10/04/2019

[**Guide on Enzyme Replacement Therapy Products**](https://www.fdaweb.com/guide-on-enzyme-replacement-therapy-products/)  
*Federal Register* notice: FDA makes available a final guidance entitled “Investigational Enzyme Replacement Therapy Products: Nonclinical Assessment.” 10/03/2019

[**Fed Reg Notice on Pemoline Corrected**](https://www.fdaweb.com/fed-reg-notice-on-pemoline-corrected/)  
*Federal Register* notice: FDA corrects a 6/4 Federal Register notice withdrawing approval of five ANDAs for pemoline products because it contained an incorrect Web site address for an archived drug safety notice. 10/03/2019

[**24 Drugs not Withdrawn Due to Safety/Efficacy: FDA**](https://www.fdaweb.com/24-drugs-not-withdrawn-due-to-safety-efficacy-fda/)  
Federal Register notice: FDA determines that 24 drug products were not withdrawn due to safety or effectiveness reasons. 10/01/2019

[**Panel Mulls Immune Responses with Metal Devices**](https://www.fdaweb.com/panel-mulls-immune-responses-with-metal-devices/)  
Federal Register notice: FDA announces an 11/13-14 Immunology Devices Panel of the Medical Devices Advisory Committee meeting to discuss immunological responses to metal-containing medical devices. 10/01/2019

[**Draft Guide on Patient-focused Drug Development**](https://www.fdaweb.com/draft-guide-on-patient-focused-drug-development-2/)  
Federal Register notice: FDA makes available a draft guidance on “Patient-Focused Drug Development: Methods To Identify What Is Important to Patients.” 10/01/2019

[**Fee for Tropical Disease Priority Review Voucher**](https://www.fdaweb.com/fee-for-tropical-disease-priority-review-voucher/)  
Federal Register notice: FDA announces the fee rate of $2,167,116 for using a tropical disease priority review voucher for fiscal year 2020\. 09/30/2019